17.04.2024 15:24:57

Why IGM Biosciences Is Rising In Pre-market?

(RTTNews) - IGM Biosciences, Inc. (IGMS) said the company's collaboration agreement with Sanofi to create and develop IgM agonist antibodies will now focus exclusively on immunology/inflammation targets. IGM will retain global rights to its technology related to the oncology targets nominated by Sanofi.

"We are very pleased with our collaboration with Sanofi and with the preclinical data that we have generated in both the immunology/inflammation and the oncology portions of the collaboration," said Fred Schwarzer, CEO of IGM Biosciences.

Shares of IGM Biosciences are up 6% in pre-market trade on Wednesday.

For More Such Health News, visit rttnews.com.

Analysen zu Sanofi S.A.mehr Analysen

16.01.25 Sanofi Neutral JP Morgan Chase & Co.
07.01.25 Sanofi Buy Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
07.01.25 Sanofi Outperform Bernstein Research
18.12.24 Sanofi Sell Deutsche Bank AG
17.12.24 Sanofi Buy Jefferies & Company Inc.
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

IGM Biosciences Inc Registered Shs 1,76 1,73% IGM Biosciences Inc Registered Shs
Sanofi S.A. (spons. ADRs) 49,00 1,66% Sanofi S.A. (spons. ADRs)
Sanofi S.A. 98,42 -0,42% Sanofi S.A.